232 related articles for article (PubMed ID: 34571336)
21. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Bottomley A; Coens C; Mierzynska J; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Puig S; Ascierto PA; Larkin J; Lorigan PC; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C; Eggermont AMM;
Lancet Oncol; 2021 May; 22(5):655-664. PubMed ID: 33857414
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
[TBL] [Abstract][Full Text] [Related]
24. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
Hamid O; Robert C; Ribas A; Hodi FS; Walpole E; Daud A; Arance AS; Brown E; Hoeller C; Mortier L; Schachter J; Long J; Ebbinghaus S; Ibrahim N; Butler M
Br J Cancer; 2018 Sep; 119(6):670-674. PubMed ID: 30202085
[TBL] [Abstract][Full Text] [Related]
25. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
26. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice.
van Zeijl MCT; van den Eertwegh AJM; Wouters MWJM; de Wreede LC; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven JJM; Haanen JBAG
Int J Cancer; 2022 Jan; 150(2):317-326. PubMed ID: 34520567
[TBL] [Abstract][Full Text] [Related]
27. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Schadendorf D; Dummer R; Hauschild A; Robert C; Hamid O; Daud A; van den Eertwegh A; Cranmer L; O'Day S; Puzanov I; Schachter J; Blank C; Salama A; Loquai C; Mehnert JM; Hille D; Ebbinghaus S; Kang SP; Zhou W; Ribas A
Eur J Cancer; 2016 Nov; 67():46-54. PubMed ID: 27596353
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
Cowey CL; Scherrer E; Boyd M; Aguilar KM; Beeks A; Krepler C
J Immunother; 2021 Jul-Aug 01; 44(6):224-233. PubMed ID: 33734142
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Long GV; Arance A; Mortier L; Lorigan P; Blank C; Mohr P; Schachter J; Grob JJ; Lotem M; Middleton MR; Neyns B; Steven N; Ribas A; Walpole E; Carlino MS; Lebbe C; Sznol M; Jensen E; Leiby MA; Ibrahim N; Robert C
Ann Oncol; 2022 Feb; 33(2):204-215. PubMed ID: 34710571
[TBL] [Abstract][Full Text] [Related]
32. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Long GV; Dummer R; Hamid O; Gajewski TF; Caglevic C; Dalle S; Arance A; Carlino MS; Grob JJ; Kim TM; Demidov L; Robert C; Larkin J; Anderson JR; Maleski J; Jones M; Diede SJ; Mitchell TC
Lancet Oncol; 2019 Aug; 20(8):1083-1097. PubMed ID: 31221619
[TBL] [Abstract][Full Text] [Related]
33. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
35. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Zhu AX; Finn RS; Edeline J; Cattan S; Ogasawara S; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan SL; Knox J; Daniele B; Webber AL; Ebbinghaus SW; Ma J; Siegel AB; Cheng AL; Kudo M;
Lancet Oncol; 2018 Jul; 19(7):940-952. PubMed ID: 29875066
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab: A Review in Advanced Melanoma.
Deeks ED
Drugs; 2016 Mar; 76(3):375-86. PubMed ID: 26846323
[TBL] [Abstract][Full Text] [Related]
38. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Armand P; Rodig S; Melnichenko V; Thieblemont C; Bouabdallah K; Tumyan G; Özcan M; Portino S; Fogliatto L; Caballero MD; Walewski J; Gulbas Z; Ribrag V; Christian B; Perini GF; Salles G; Svoboda J; Zain J; Patel S; Chen PH; Ligon AH; Ouyang J; Neuberg D; Redd R; Chatterjee A; Balakumaran A; Orlowski R; Shipp M; Zinzani PL
J Clin Oncol; 2019 Dec; 37(34):3291-3299. PubMed ID: 31609651
[TBL] [Abstract][Full Text] [Related]
40. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]